Pharmacological, pharmacokinetic and clinical profile of meloxicam

Drugs of Today

Volumn 34, Issue SUPPL. A, 1998, Pages 1-22

  Degner, Frank ^a   Türck, Dietrich ^a   Pairet, Michel ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENZYME INHIBITION; NONHUMAN; PROSTAGLANDIN SYNTHESIS; REVIEW;

EID: 0031913321     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature (New Biol) 1971, 231: 232-5.
2. Fletcher, B.S., Kujubu, D.A., Perrin, D.M., Herschmann, H.R. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992, 267: 4338-44.
3. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990, 265: 16737-40.
4. Pairet, M., Engelhardt, G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: Possible physiological and therapeutic implications. Fundam Clin Pharmacol 1996, 10(1): 1-15.
5. Vane, J.R. Towards a better aspirin. Nature 1994, 367: 215-6.
6. Engelhardt, G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 1996, 35 (Suppl. 1): 4-12.
7. Engelhardt, G., Homma, D., Schlegel, K., Utzmann, R., Schnitzler, C. Antiinflammatory, analgesic, antipyretic and related properties of meloxicam, a new nonsteroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995, 44: 423-33.
8. Engelhardt, G., Homma, D., Schnitzler, C. Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 1995, 44: 548-55.
9. Laird, J.M.A., Herrero, J.F., Garcia de la Rubia, P., Cervero, F. Analgesic activity of the novel COX-2 preferring NSAID, meloxicam in mono-arthritic rats: Central and peripheral components. Inflamm Res 1997, 46: 203-10.
10. Cross, A.R., Budsberg, S.C., Keefe, T.J. Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. Am J Vet Res 1997,
11. van Bree, H., Justus, C., Quirke, J.F. Preliminary observations on the effects of meloxicam in a new model for acute intra-articular inflammation in dogs. Vet Res Commun 1994, 18: 217-34.
12. Justus, C., Quirke, J.F. Dose-response relationship for the antipyretic effect of meloxicam in an endotoxin model in cats. Vet Res Commun 1995, 19: 321-30.
13. Bassleer, C., Magotteaux, Y., Geenan, V., Malaise, M. Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. Pharmacology 1997, 54: 49-56.
14. Mohr, W., Lehmann, H., Engelhardt, G. Chondroneutrality of meloxicam in rats with spontaneous osteoarthritis of the ankle joint. J Rheumatol 1997, 56: 21-30.
15. Engelhardt, G., Bogel, R., Schitzler, C., Utzmann, R. Meloxicam: Influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol 1996, 51: 29-38.
16. Pairet, M., Churchill, L., Engelhardt, G. Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs. In: New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules. N. Bazan, J.H. Botting, J.R. Vane (Eds). Kluwer: Dordrecht 1996, 23-38.
17. Churchill, L., Graham, A.G., Shih, C.K., Pauletti, D., Farina, P.R., Grob, P.M. Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacology 1996, 4: 125-35.
18. Engelhardt, G., Bogel, R., Schnitzler, C., Utzmann, R. Meloxicam: Influence on arachidonic acid metabolism. Part I. In vitro findings. Biochem Pharmacol 1996, 51: 21-8.
19. Pairet, M., Lidbury, P.A., Engelhardt, G., Trummlitz, G., Vane, J.R. Meloxicam: Cyclo-oxygenase selectivity, anti-inflammatory activity and gastric and renal safety. Inflamm Res 1995, 44 (Suppl. 3): Abst W15/24.
20. Pairet, M., van Ryn, J., Manz, A. et al. Differential inhibition of COX-1 and COX-2 by NSAIDs: A summary of results obtained using various test systems. In: Selective Cyclooxygenase-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. J. Vane, J. Botting (Eds.). Kluwer: Dordrecht 1997, in press.
21. Patrignani, P., Panara, M.R., Santini, G. et al. Differential inhibition of the cyclooxygenase activity of prostaglandin endoperoxide synthase isozymes in vitro and ex vivo in man. Prostaglandins Leukot Essent Fatty Acids 1996, 55 (Suppl. 1): Abst P115.
22. Riendeau, D., Percival, M.D., Boyce, S. et al. Biochemical and pharmacological profile of tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 1997, 121: 105-17.
23. Ogino, K., Hatanaka, K., Kawamura, M., Katori, M., Harada, Y. Evaluation of pharmacological profile of meloxicam as an antiinflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology 1997, 55(1): 44-53.
24. Vergne, P., Bertin, P., Liagre, B. et al. Differential inhibition of COX-1 and COX-2 by non-steroidal antiinflammatory drugs in cultured synoviocytes. Arthritis Rheum 1997, 40(9): S93.
25. Blanco, F., Guitian, R., Moreno, J. et al. NSAIDs effect on COX-1 and COX-2 activity in human articular chondrocytes. Arthritis Rheum 1997, 40(9): S88.
26. Stichtenoth, D.O., Wagner, B., Frolich, J.C. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Invest Med 1997, 45 (2): 44-9.
27. Twomey, B.M., Dale M.M. Cyclooxygenase-independent effects of non-steroidal anti-inflammatory drugs on the neutrophil respiratory burst. Biochem Pharmacol 1992, 43: 413-8.
28. Rainsford, K.D., Ginsburg, I., Gadd, S.J. A comparison between the effects of meloxicam and other NSAIDs on the production of oxyradicals by polymorphonuclear leucocytes. Inflammopharmacology 1997, 5: 9-19.
29. Garcia-Vicuna, R. Prevention of cytokine-induced changes in leukocyte adhesion receptors by non-steroidal anti-inflammatory drugs from the oxicam family. Arthritis Rheum 1997, 40: 143-53.
30. Türck, D., Roth, W., Busch, U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996, 35 (Suppl. 1): 13-6.
31. Türck, D., Busch, U., Heinzel, G., Narjes, H., Nehmiz, G. Effect of food on the pharmacokinetics of meloxicam after oral administration. Clin Drug Invest 1995, 5: 270-6.
32. Türck, D., Schwarz, A., Hoffler, D., Narjes, H., Nehmiz, G., Heinzel, G. Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: A comparison with healthy vol- unteers. Eur J Clin Pharmacol 1996, 51: 309-19.
33. Busch, U., Heinzel, G., Narjes, H. The effect of cholestyramine on the pharmacokinetics of meloxicam a new non-steroidal anti-inflammatory drug (NSAID) in man. Eur J Clin Pharmacol 1995, 48: 269-72.
34. Narjes, H., Türck, D., Busch, U., Heinzel, G., Nehmiz, G., Su, C.A.P.F. Parenteral tolerability of meloxicam in healthy volunteers. Scand J Rheumatol 1996, 25 (Suppl. 106): 61.
35. Narjes, H., Türck, D., Busch, U., Heinzel, G., Nehmiz, G. Pharmacokinetics and tolerability of meloxicam after i.m. administration. Br J Clin Pharmacol 1996, 36: 135-9.
36. Türck, D., Busch, U., Heinzel, G., Narjes, H. Clinical pharmacokinetics of meloxicam. Arzneim-Forsch 1997, 47: 253-8.
37. Türck, D., Narjes, H., Heinzel, G., Sigmund, R. Intramuscular pharmacokinetics of 7.5 mg meloxicam. ILAR Cong Rheumatol (Singapore) 1997, 160.
38. Schepers, C., Tuerck, D., Narjes, H., Bluhmki, E. Pharmacokinetics of 7.5 mg meloxicam (UH-AC 62 XX) capsules after single and multiple administration p.o. over 7 days in healthy young male and female volunteers. Boehringer Ingelheim, data on file.
39. Tuerck, D., Su, C.A.P.F., Heinzel, G., Bluhmki, E. Relative bioavailability of the 7.5 mg meloxicam suppository in comparison with the 7.5 mg meloxicam capsule in steady state in healthy volunteers. Boehringer Ingelheim, data on file.
40. Busch, U., Schmid, G., Heinzel, G. et al. Animal pharmacokinetics of meloxicam and their relevance to humans. Drug Metab Dispos, accepted.
41. Schmid, J., Busch, U., Heinzel, G., Bozler, G., Kaschke, S., Kummer, M. Meloxicam pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos 1995, 23: 1206-13.
42. Degner, F., Heinzel, G., Busch, U. Transsynovial kinetics of meloxicam. Scand J Rheumatol 1994, Suppl. 98: 121.
43. Lapicque, F., Gillet, P., Vignon, E. et al. Diffusion of meloxicam into synovial fluid after a single oral dose. Rheumatol Eur 1996, 25 (Suppl. 1): 444.
44. Chesne, C., Guyomard, C., Guillozo, A., Schmid, J., Ludwig, E., Sauter, T. Metabolism of meloxicam by human liver involves cytochromes 209 and 3A4. Exp Toxicol Pathol 1996, 48: 406.
45. Kretz-Rommel, A., Boelsterli, U.A. Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal protein: Retention of the glucuronide acid moiety in the adduct. Drug Metab Dispos 1994, 22: 956-61.
46. Distel, M., Müller, C., Bluhmki, E., Fries, J. Safety of meloxicam: A global analysis of clinical trials. Br J Rheumatol 1996, 35 Suppl. 1: 68-77.
47. Busch, U., Heinzel, G., Narjes, H. et al. Pharmacokinetics of meloxicam in patients with hepatic cirrhosis in comparison with healthy volunteers. Clin Drug Invest 1996, 11: 97-107.
48. Boulton-Jones, J.M., Geddes, C.G., Heinzel, G., Türck, D., Nehmiz, G., Bevis, P.J.R. Meloxicam pharmacokinetics in renal impairment. Br J Clin Pharmacol 1997, 43: 35-40.
49. Acerbi, D., Bufalino, L., Cesari, F., D'Ambrosio, E., Mansanti, P., Scali, G. Pharmacokinetic study on piroxicam at the steady state in elderly subjects and younger adults after administration of piroxicam β-cyclodextrin. Int J Clin Pharm Res 1988, 8: 175-80.
50. Richardson, C.J., Blocka, L.N., Ross, S.G., Verbeeck, R.K. Effect of age and sex on piroxicam disposition. Clin Pharmacol Ther 1985, 37: 13-8.
51. Türck, D., Su, C.A.P.F., Heinzel, G., Busch, U., Bluhmki, E., Hoffmann, J. Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol 1997, 51: 421-5.
52. Türck, D., Narjes, H., Duong, D.N., Heinzel, G., Sigmund, R., Su, C.A.P.F. Lack of interaction between meloxicam and acenocoumarol. ILAR Cong Rheumatol (Singapore) 1 997, 160.
53. Müller, F.O., Schall, R., de Vaal, A.C., Groenewoud, G , Hundt, H.K.L., Middle, M.V. Influence of meloxicam on furosemide pharmacokinetics and pharmaco- dynamics in healthy volunteers. Eur J Clin Pharmacol 1995, 48: 247-51.
54. Müller, F.O., Middle, M.V., Schall, R., Terblanche, J., Hundt, H.K.L., Groenewoud, G. An evaluation of the interaction of meloxicam with furosemide in patients with compensated chronic cardiac failure. Br J Clin Pharmacol 1997, 44: 393-8.
55. Degner, F.L., Heinzel, G., Narjes, G., Türck, D. Interaction of meloxicam on the pharmacokinetics of β-acetyldigoxin. Br J Clin Pharmacol 1995, 40: 486-8.
56. Hübner, G., Sander, O., Degner, F.L., Türck, D., Rau, R. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol 1997, 24: 845-51.
57. Patoia, L., Santucci, L., Furno, M. et al. A 4-week double-blind parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg. piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 1996, 35 (Suppl. 1): 61-7.
58. Bevis, P.J.R., Bird, H.A., Lapham, G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br J Rheumatol 1996, 35 (Suppl. 1): 56-60.
59. Lemmel, E.M., Bolten, W., Burgos-Vargas, R. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol 1997, 24: 282-90.
60. Noble, S., Balfour, J.A. Meloxicam. Drugs 1996, 51 (3): 424-30.
61. Wojtulewski, J.A., Schattenkirchner, M., Barcelo, P. et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996, 35 (Suppl. 1): 22-9.
62. Huskisson, E.C., Ghozlan, R., Kurthen, R., Degner, F.L., Bluhmki, E. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol 1996, 35 (Suppl. 1): 22-8.
63. Lund, B., Distel, M., Bluhmki, E. A double-blind placebo controlled study of three dif- ferent doses of meloxicam in patients with osteoarthritis of the knee. Scand J Rheumatol 1994, Suppl. 98: Abst 117.
64. Hosie, J., Distel, M., Bluhmki, E. Meloxicam in osteoarthritis: A six-months, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996, 35 (Suppl. 1): 39-43.
65. Goei Thé, H., Lund, B., Distel, M.R., Bluhmki, E. A double-blind randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthr Cartil 1997, 5: 283-8.
66. Hosie, J., Distel, M., Bluhmki, E. A six month, double-blind study comparing meloxicam 15 mg with piroxicam 20 mg in osteoarthritis. Rheumatol Eur 1995, 24 (Suppl. 3): Abst E50.
67. Lindén, B., Distel, M., Bluhmki, E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996, 35 (Suppl. 1): 35-8.
68. Kahan, A. MELISSA - The meloxicam large-scale international safety assessment. XIX ILAR Cong Rheumatol (Singapore) 1997, 155.
69. Auvinet, B., Ziller, R., Appelboom, T., Velicitat, P. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin Ther 1995, 17: 1078-90.
70. Bosch, H.C., Hettich, M., Degner, F.L. Efficacy and tolerability of intramuscular and oral meloxicam: A comparison with piroxicam in acute lumbago. Rheumatol Eur 1996, 25 (Suppl. 1): Abst 431.
71. Colberg, K., Hettich, M., Sigmund, R., Degner, F.L. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: A comparison with intramuscular and oral diclofenac in patients with acute lumbago. Curr Med Res Opin 1996, 13: 363-77.
72. Ghozan, P.R., Bernhardt, M., Velicitat, P., Bluhmki, E. Tolerability of multiple administration of intramuscular meloxicam: A comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Br J Rheumatol 1996, 35 (Suppl. 1): 51-5.
73. Schattenkirchner, M. Meloxicam: A selective COX-2 inhibitor non-steroidal antiinflammatory drug. Expert Opin Invest Drugs 1997, 6(3): 321-34.
74. Langman, M.J.S., Weil, J., Wainwright, P., Lawson, D.H., Rawlins, M.D. Logan, R.F.A. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343: 1075-8.
75. Fries, J.F. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991, 18 (Suppl. 28): 6-10.
76. García Rodriguez, L.A. Epidemiology of the relative safety of NSAIDs. In: Selective Cyclooxygenase-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. J. Vane, J. Bottig (Eds.). Kluwer: Dordrecht 1997, in press.
77. García Rodriguez, L.A., Jick, H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343: 769-72.
78. Zeidler, H., Degner, F., Hettich, M. Comparative pharmacoepidemiologic analysis of gastrointestinal safety of selective COX-2 inhibition by meloxicam compared to other marketed NSAIDs. Eur J Clin Pharmacol 1997, 52 (Suppl): Abst 327.